PeptideCalc

MK-677: Ibutamoren — oral growth-hormone secretagogue

An orally active ghrelin mimetic that raises growth hormone and IGF-1 — investigational, never approved, and known to raise blood sugar in trials.

What is MK-677?

MK-677 (ibutamoren) is an orally active growth-hormone secretagogue — a non-peptide ghrelin mimetic that raises growth hormone (GH) and IGF-1. Unlike the injectable GH peptides, it's taken by mouth, which is part of its appeal. It has been studied in clinical trials but was never approved, and a key finding is that it raises fasting blood glucose.

How MK-677 works (mechanism)

MK-677 activates the ghrelin receptor (GHS-R1a), stimulating pulsatile GH release and increasing IGF-1, with effects sustained by oral dosing. In a 2-year randomised trial in healthy older adults, 25 mg daily increased GH and IGF-1 toward youthful levels and increased fat-free mass — but also produced a sustained increase in fasting blood glucose and insulin resistance [1]. Earlier work showed prolonged oral MK-677 could also affect sleep and GH secretion [3].

Why it's studied / reported uses

Growth hormone, IGF-1 & body composition

MK-677 is studied for raising GH/IGF-1 and increasing fat-free mass; the 2-year Nass trial is the largest controlled human dataset [1][2]. It did not improve strength in that trial.

Appetite & sleep

As a ghrelin mimetic it increases appetite, and older research examined effects on sleep quality [3].

Dosing reported in studies

⚠ Not a recommended dose. The figures below are what studies or protocols reported, for educational reference only.
Clinical / trial data
Reported research range
10–25 mg per day
Frequency: once daily (oral)
Route: oral
Ibutamoren, an orally active GH secretagogue studied in clinical trials.

Sources: Nass et al. (2008) — Ann Intern Med · Murphy et al. (1998) — JCEM

Investigational; can increase appetite, water retention and blood glucose. These figures reflect what studies or protocols reported — not a recommendation and not tailored to you.

Calculate a dose in the reconstitution calculator →

Safety & side effects

MK-677 is investigational and not FDA-approved. The best-documented concern is a rise in fasting blood glucose and insulin resistance, seen over 2 years at 25 mg/day [1]. Other reported effects include increased appetite, water retention and lethargy. It is prohibited in competitive sport. People with, or at risk of, diabetes should be especially cautious. Consult a licensed physician.

Studies & references

  1. Effects of an oral ghrelin mimetic (MK-677) on body composition in healthy older adults — 2-year randomised trial — NCBI / PMC2757071 (Nass et al., Ann Intern Med 2008)
  2. Effects of an oral ghrelin mimetic on body composition (PubMed record) — PubMed 18981485
  3. MK-677, an orally active GH secretagogue — early clinical study — PubMed 9467534

Frequently asked questions

Is MK-677 FDA-approved?

No. MK-677 (ibutamoren) is investigational and was never approved for any indication. It is also prohibited in competitive sport.

Does MK-677 raise blood sugar?

Yes — in the 2-year Nass trial, 25 mg/day raised fasting glucose and reduced insulin sensitivity. People with or at risk of diabetes should be cautious and consult a doctor.

How is MK-677 dosed in studies?

The most-studied dose is 25 mg once daily (oral); community use often cites 10–25 mg/day (see the dosing section). This is not a recommendation.

Is MK-677 a SARM?

No. It's a growth-hormone secretagogue (ghrelin mimetic), often grouped with SARMs in the sports-supplement world but mechanistically different.

Related peptides